anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a medicine composition having strongly immunopoterntiative actions and infection protecting actions, useful as a preventive/therapeutic agent for mastitis, septic shock, eukopoenia, etc. SOLUTION: This medium composition comprises vitamin B2 (preferably riboflavin, riboflavin tetrabutyrate, sodium riboflavin phosphate, flavin mononucleotide or flavin adenine dinucleotide) and m-cresol. The dose of vitamin B2 is preferably 1-25 mg based on 1 kg weight. In the case of administering the composition as an injection, the amount of m-cresol is preferably 0.05-0.25 W/V%, based on the total volume of the injection. The administration form of the medicine composition is preferably an injection and the composition can be administered by intramuscular injection, intravenous injection, subcutaneous injection, etc. In the case of the injection, the injection can be formulated with a surfactant such as Tween 80 or the like, an emulsifying agent such as gum arabic, a soothing agent such as benzyl alcohol or the like, if required.
The present invention relates to an ethanol foam sclerosing agent for vascular anomalies and a preparation method thereof. The ethanol foam sclerosing agent includes absolute ethanol, water, Tween 80 and a stabilizer. The ethanol foam sclerosing agent further includes hyaluronic acid. The mass composition of the ethanol foam sclerosing agent includes 32-42% of absolute ethanol, 0.5-2% of Tween 80, 0-25% (excluding 0) of egg yolk lecithin, 0-2% (excluding 0) of hyaluronic acid, and the balance of water. The stabilizer is hyaluronic acid or glycerin. Foam is prepared by the Tessari method. While the original therapeutic effect of ethanol is not changed, the side effect of the ethanol is significantly reduced.
<P>PROBLEM TO BE SOLVED: To provide a detergent for small animals able to sufficiently apply a detergent solution to the skin simply by one hand in washing the body of a small animal, especially a dog, a cat, a rabbit and the like, sufficiently remove pet's sebum and keep the skin of the pet to be healthy.  <P>SOLUTION: The detergent in vessel for small animal is prepared by housing the detergent solution in a vessel. The vessel comprises the vessel body 1 for housing the detergent solution and a cap unit 2. The cap unit has an almost conical nozzle unit 3 having a discharge port of the detergent solution. The length of the nozzle unit is ≥10 mm from the base of the nozzle unit.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Malignancies (lymphoma, basal \& squamous skin cancer, non-cutaneous solid tumor, \& Wegener's granulomatosis), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
BACKGROUND: Cardiac arrest is a common and devastating emergency of both the heart and brain. More than 380,000 patients suffer out-of-hospital cardiac arrest annually in the USA. Induced cooling of comatose patients markedly improved neurological and functional outcomes in pivotal randomized clinical trials, but the optimal duration of therapeutic hypothermia has not yet been established.
METHODS: This study is a multi-center randomized, response-adaptive, duration (dose) finding, comparative effectiveness clinical trial with blinded outcome assessment. We investigate two populations of adult comatose survivors of cardiac arrest to ascertain the shortest duration of cooling that provides the maximum treatment effect. The design is based on a statistical model of response as defined by the primary endpoint, a weighted 90-day mRS (modified Rankin Scale, a measure of neurologic disability), across the treatment arms. Subjects will initially be equally randomized between 12, 24, and 48 h of therapeutic cooling. After the first 200 subjects have been randomized, additional treatment arms between 12 and 48 h will be opened and patients will be allocated, within each initial cardiac rhythm type (shockable or non-shockable), by response adaptive randomization. As the trial continues, shorter and longer duration arms may be opened. A maximum sample size of 1800 subjects is proposed. Secondary objectives are to characterize: the overall safety and adverse events associated with duration of cooling, the effect on neuropsychological outcomes, and the effect on patient-reported quality of life measures.
DISCUSSION: In vitro and in vivo studies have shown the neuroprotective effects of therapeutic hypothermia for cardiac arrest. We hypothesize that longer durations of cooling may improve either the proportion of patients that attain a good neurological recovery or may result in better recovery among the proportion already categorized as having a good outcome. If the treatment effect of cooling is increasing across duration, for at least some set of durations, then this provides evidence of the efficacy of cooling itself versus normothermia, even in the absence of a normothermia control arm, confirming previous RCTs for OHCA survivors of shockable rhythms and provides the first prospective controlled evidence of efficacy in those without initial shockable rhythms.
TRIAL REGISTRATION: ClinicalTrials.gov NCT04217551. Registered on 30 December 2019.
This Group will receive generalized supervised antenatal exercises that are covered in three phases and basic antenatal education. There will be 3 sessions per week for 10weeks conducted for generalized antenatal exercises including Aerobics, Endurance and Pelvic Floor Muscle Training.
The experimental group will receive a phone call intervention 3 days post-op. During this phone call, the patient will be asked questions using a study questionnaire based on the most frequent indications for readmission post colorectal surgery. Based on the responses, patients will be advised to maintain the scheduled appointment, visit the clinic within 48 hours, or go to the Emergency Department immediately.
The invention discloses a capsule with the functions of beautifying and reducing blood fat and a preparation method thereof. The main components of the capsule with the functions of beautifying and reducing blood fat comprise sodium hyaluronate, chitosan, pectin, L-carnitine tartrate and the like. In addition, the invention also discloses a preparation method of the capsule with the functions of beautifying and reducing blood fat. According to the invention, two natural macromolecular materials, namely sodium hyaluronate and chitosan, are innovatively introduced into the field of functional foods, and the aim of promoting the synthesis amount of hyaluronic acid in a human body is fulfilled by oral administration instead of injection, so that the skin moisture is better improved, the aging is delayed, and the joint function is improved. Meanwhile, the advantage of reducing the fat content of the human body is achieved by utilizing the characteristic that chitosan can regulate the balance of intestinal flora and the advantage of reducing the fat content. The invention has reasonable process, strong operability and wider market prospect.
Subjects diagnosed with Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (LA-OPSCC) will receive treatment with MET-4 in addition to standard of care CRT. MET-4 is administered orally as an initial daily loading dose over 2 days followed by a daily maintenance dose of MET-4 and will be administered until week 4 of CRT or unacceptable toxicity whichever occurs earlier and in the absence of criteria to discontinue MET-4.
PURPOSE: A composition containing Vaccinium uliginosum extract is provided to reduce the number of eosinophil and blood IgE level and to suppress the causes of atopic dermatitis. CONSTITUTION: A composition for preventing or treating atopic dermatitis contains Vaccinium uliginosum extract as an active ingredient. The Vaccinium uliginosum extract is isolated using hot water at 80-100°C. The composition is a pharmaceutical composition or food composition. A cosmetic composition for treating atopic dermatitis contains a cosmetically effective amount of the extract and cosmetically acceptable carrier. The extract is isolated from Vaccinium uliginosum fruits, leaves, or bark using a solvent.
With the growing adoption of robotic techniques in gynecologic surgery, the advantages of minimally invasive procedures over traditional open surgery, such as reduced postoperative pain and quicker recovery, are clear. Yet, establishing an effective multimodal analgesic regimen remains a challenge. This retrospective study from a tertiary care center aimed to assess the analgesic efficacy of the rectus sheath block (RSB) on postoperative pain and opioid consumption after robotic gynecologic surgery. Between June 2022 and March 2023, 20 patients who underwent robotic gynecologic surgery were evaluated. Key parameters included postoperative visual analog scale scores, opioid consumption, and postoperative nausea/vomiting instances. Anesthesia protocols were standardized, with postsurgical pain management involving RSB and a patient-controlled analgesia device filled with morphine. Patients showed an average morphine intake of 8.2 ± 5.09 mg over the initial 24 hours postsurgery. During mobilization, average pain scores were consistently low, with no correlation identified between opioid consumption and age or body mass index. 40% of patients reported postoperative nausea on the first day, and no complications linked to the RSB were observed. The study underlines the potential of integrating RSB in a multimodal analgesic regimen after robotic gynecologic surgery. Its application may lead to reduced opioid consumption and more efficient postoperative pain management. Further randomized controlled trials are recommended to validate these findings.
This is the placebo group. Participants in this group will receive aromatherapy tabs in the scent of almond oil. Tabs will worn on a badge for a total of 72 hours, and participants will replace the aroma tabs every 12 hours.
The efficacy of DAYBUE for the treatment of Rett syndrome was established in a 12-week randomized, double-blind, placebo-controlled study in patients with Rett syndrome 5 to 20 years of age (Study 1; NCT04181723). 

Patients (N=187) had a diagnosis of typical Rett syndrome according to the Rett Syndrome Diagnostic Criteria with a documented disease-causing mutation in the MECP2 gene. Patients were randomized to receive DAYBUE (N=93) or matching placebo (N=94) for 12 weeks. The DAYBUE dosage was based on patient weight to achieve similar exposure in all patients [see Dosage and Administration (2.1)].

The co-primary efficacy measures were change from baseline after 12 weeks of treatment in the total score of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Clinical Global Impression-Improvement (CGI-I) score. The RSBQ is a 45-item rating scale completed by the caregiver that assesses a range of symptoms of Rett syndrome (breathing, hand movements or stereotypies, repetitive behaviors, night-time behaviors, vocalizations, facial expressions, eye gaze, and mood). Each item is scored as 0 (not true), 1 (somewhat or sometimes true), or 2 (very true or often true), with a maximum possible score of 90 points. Lower scores reflect lesser severity in signs and symptoms of Rett syndrome. The CGI-I is rated by clinicians to assess whether a patient has improved or worsened on a 7-point scale (1=very much improved to 7=very much worse) in which a decrease in score indicates improvement.

Treatment with DAYBUE demonstrated a statistically significant difference in favor of DAYBUE as compared to placebo on the co-primary efficacy endpoints, the change from baseline in RSBQ total score, and the CGI-I score at week 12 (Table 3, Figure 1, and Figure 2).

Figure 1 Change From Baseline in RSBQ Total Score in Study 1

Figure 2 Distribution of CGI-I Scores for Patients Completing Study 1
The invention discloses a solid aromatic anti-alcohol agent and a preparation method thereof. The solid aromatic anti-alcohol agent is prepared from the following components in percentage by weight: 0.75-1.50% of anti-alcohol essence, 0.50-1.50% of a solid air freshening adhesive, 8.00-10.00% of an efficient solubilizer, 0.40-0.60% of a preservative and the balance of distilled water. The preparation method comprises the following steps of preparing the anti-alcohol essence; solubilizing the anti-alcohol essence; preparing a gel colloid; mixing the anti-alcohol essence with the gel colloid and the like. Finally, the obtained solid aromatic anti-alcohol agent is pure natural, free from toxic and harm and safe. Meanwhile, the solid aromatic anti-alcohol agent disclosed by the invention contains components such as lavender oil, so that the solid aromatic anti-alcohol agent gives out fresh and gentle scent of flowers and grass. The solid aromatic anti-alcohol agent not only can purify air, but also can dispel fatigue, prevent depression and pacify emotion. The solid aromatic anti-alcohol agent can continuously release scent for 3-5 days and is free from environmental pollution.
The overarching goal of the Jauntly mobile app was to experience exercises that encourage one to take care of oneself emotionally, improve positive emotions, and decrease stress and other negative emotions. The user interacted with the app through evidence-based activities (e.g. writing gratefulness notes, helping others, practicing mindfulness). The activities were selected based on the goals the user selected upon initiation of program and throughout engagement with the app. In order to promote sustained use of the program and mastery of the positive emotion based skills, the design of the program included activities that range in difficulty so that the user could progress and improve (i.e., simple "1 and done" types of goals versus multi-week goals).

Research in positive psychology interventions suggests that increases in well-being are highest when the activity: 1) fits the person's interests and values and 2) is performed neither too frequently nor too seldom. Because of our desire to have a product with long-lasting usability and sustained engagement, it was critical that there were a diverse number of activities from which individuals could choose based on interest, current mood, and past success. The Jauntly user experience is structured around free use of the app partnered with regular emails, in-app messaging, videos, and articles. Emails remind users to utilize program content (including users in the control group who were reminded to visit the stress-management website). Use of the app and viewing of videos and other content is not restricted and users are able to self-tailor use according to their interest.
The presence of mutations in the BRCA1 gene (MIM: 113705) is widely recognized as a significant genetic predisposition for ovarian cancer. This study investigated the genomic mutations in a Chinese family with a history of ovarian, breast, and rectal adenocarcinoma. A novel germline mutation (Phe1695Val) in BRCA1 was identified through whole-exome sequencing. Subsequently, we performed whole-genome sequencing to identify somatic mutations and analyze mutational signatures in individuals carrying the novel germline mutation. Our findings revealed a correlation between somatic mutational signatures and the BRCA1 germline mutation in the proband with ovarian cancer, while no such association was observed in the tumor tissue from the patient with breast cancer. Furthermore, distinct somatic driver mutations were identified, a truncated mutation in the TP53 gene in the ovarian tumor tissue, and a hotspot mutation in the PIK3CA gene in the breast cancer. According to our findings, the BRCA1 F1695V mutation is linked to ovarian cancer susceptibility in the family and causes specific somatic mutational profiles.
<P>PROBLEM TO BE SOLVED: To provide a drug having an ACE inhibiting effect.  <P>SOLUTION: The angiotensin-converting enzyme inhibitor includes galangal, rosewood, and henna or their extracts and has an antihypertensive effect. The galangal includes a dried material of the rootstock of galangal itself, its crushed material, its extract obtained by supercritical fluid extraction, and its crude extract with water, or an organic solvent such as an alcohol, an ether or acetone. The rosewood includes a dried material of the heartwood of rosewood itself, its crushed material, its extract obtained by supercritical fluid extraction, and its crude extract with water, or an organic solvent such as an alcohol, an ether or acetone. The henna includes a dried material of the leaves of henna itself, its crushed material, its extract obtained by supercritical fluid extraction, and its crude extract with water, or an organic solvent such as an alcohol, an ether or acetone.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The invention discloses a sleep aid pastry and a making process of the pastry, which is to provide the sleep aid pastry that has abundant nutrition, functions of nourishing the heart and enriching the blood and is convenient to be eaten, and the making process of the pastry. The materials comprise the following components: 60-70 percent of sticky rice, 15-25 percent of white sugar, 5-10 percent of seed of thorny jujube trees and 5-10 percent of cedar seeds according to weight proportion. The making process of the sleep aid pastry is materials preparation, stirring, formation, pastry cutting, pastry baking, packing and warehouse entry. The sleep aid pastry of the invention is combined by natural materials and reserves effective elements of each component. The invention has the advantages of simple process, abundant nutrition, convenient eating and carryover and excessive fatigue curing, heart blood loss, foggy head, strange dreams at night, severe palpitation and fear, forgettery. Regularly taking can comfort the heart and nerve, and improve the sleep quality. The invention is an excellent health food.
The invention discloses a novel duck reovirus strain NDRV-JM85 with a preservation number of CCTCC NO: V201127. The novel duck reovirus strain NDRV-JM85 is used as a virus seed to inoculate an allantoic cavity of a muscovy duck embryo and obtain a virus-containing allantoic fluid, or inoculate an MDEF cell to obtain cytotoxin when a CPE reaches 75%. The virus liquid is inactivated by formaldehyde and added with a white oil adjuvant, and the mixture is mixed thoroughly to from a safe and effective oil emulsion inactivated vaccine for novel duck reovirus. The vaccine is used to immunize a laying hen three times, with an immunization interval of 21 days and 1.0 ml for each hen at each time. Eggs laid 21-63 days after the three immunizations are gained, and extracted yolk and a proper amount of disinfected normal saline is prepared into a hyperimmune antibody preparation for the novel duck reovirus. A duckling without an NDRV maternal antibody is injected with the antibody preparation at 1-2 days old for 0.5ml / duckling, or a duckling with a maternal antibody is injected with the antibody preparation at 10 days old for 1.0 ml / duckling, so as to prevent and control the novel duck reovirus. The invention applies to large-scale production under a GMP condition.
FIELD: chemistry of proteins, medicine, endocrinology, pharmacy. SUBSTANCE: invention proposes a derivative of polypeptide containing primary structure H 2 N-R-COOH where R means amino acid sequence ID No 2: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp- -Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala- -Trp-Leu-Val-Lys-Gly-Arg-Gly or its pharmaceutically acceptable salts. Derivative exhibits value pI 4.0 or less or pI 7.0 or above and shows insulinotropic activity. Derivative is a esterified, amidated, deamidated, alkylated or acetylated polypeptide. Polypeptide is synthesized by interaction with cyclic anhydride, additional C-terminal basic and/or neutral amino acid or connected acids, or by combination of two or more these variants. Derivative of the mentioned above primary structure at condition that the above mentioned derivative is not complex C-terminal alkylester containing (C 1 -C 6 )-alkyl of linear or branched chain of the primary structures and at condition that the mentioned above derivative is not C-terminal carboxamide of the formula CONR 2 R 3  of the mentioned above primary structure where R 2  and R 3  means each means independently H or (C 1 -C 6 )-alkyl of linear or branched chain. Invention describes a pharmaceutical composition on the basis of the above indicated polypeptide derivative that can be used for treatment of diabetic patients. Invention proposes a method for enhancement of insulin effect in mammalian and a method of treatment of diabetic patients using the above indicated polypeptide. EFFECT: enhanced effectiveness of polypeptide for diabetic patients treatment. 23 cl, 1 tbl, 1 ex
Participants will receive intravitreal ranibizumab 0.5 mg injections starting on Day 1. Patients will receive intravitreal ranibizumab 0.5 mg Q4W until Week 44. At the Week 48 study visit, patients will receive the PDS implant (pre-filled intraoperatively with ranibizumab 100 mg/mL), move to the long-term extension phase of the study and receive Q24W refill exchanges until the end of study. If patients are unable to attend the Week 48 visit due to extenuating circumstances, they should return no later than the next scheduled visit (Week 52), when they will receive the PDS implant. Patients will attend monthly visits up to Week 96 and bi-monthly visits, thereafter.
OBJECTIVES: I. Determine the maximum tolerated dose of DX-8951f in patients with advanced myelodysplastic syndromes, refractory acute myeloid or lymphocytic leukemia, refractory or transformed chronic lymphocytic leukemia, or chronic myelogenous leukemia in blastic phase. II. Evaluate the quantitative and qualitative toxic effects of this regimen and determine the duration and reversibility of these effects in these patients. III. Make a preliminary determination of the antileukemic activity of this regimen in these patients. IV. Evaluate the pharmacokinetics of this regimen in these patients.

OUTLINE: This is a dose escalation study. Patients receive DX-8951f IV over 30 minutes daily for 5 days. Treatment continues every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of DX-8951f until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months until death.

PROJECTED ACCRUAL: Approximately 20-25 evaluable patients will be accrued for this study.
Subjects will be randomized to receive either melatonin or placebo. Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT. Patients with localized breast cancer will receive standard-of-care RT as determined by the treating physician. The RT regimens include: (1) 1 week of accelerated (APBI); (2) 3-4 weeks of an accelerated hypofractionation RT schedule; and (3) 6-8 weeks of a standard RT schedule. No additional concomitant medication or supportive care guidelines are required for this study. Subjects will receive daily melatonin or placebo beginning the night before their course of RT and for an additional 2-week period that extends beyond the conclusion of their RT. Subjects will be given a Study Diary to record their use of study medication. Patients will be followed for 60 days after removal from the study treatment or until death, whichever occurs first. Patients removed from the study treatment for unacceptable adverse events (AEs) will be followed until resolution or stabilization of the adverse event.